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1. Introduction 
Natural occurrence of arsenic in groundwater is found in the Americas, European, Western 
Africa, and Asia including Taiwan, Japan, southern Thailand and China where in some 
areas, drinking water supplies are primarily based on groundwater resources 2. For general 
population in southwestern coast Taiwan, the major arsenic exposure resource is the 
ingestion of arsenic contaminated groundwater. The residents have used high-arsenic 
contaminated well water for drinking and cooking for many decades since early 1910s. The 
tap water supply system was implemented in the early 1960s, however artesian well water 
has not been used for drinking or cooking until mid-1970s 3. 
Because arsenic toxicity operates in a highly nonlinear manner and different levels of exposure 
measurements applied result in large discrepancy across studies and made it difficult to come 
up a reliable dose-response relationship for arsenic hazard. There is a long-standing 
observation of individual variability in susceptibility to arsenic toxicity 4 and this variation 
may be partly due to differences in age and sex distribution across areas, and also individual 
arsenic metabolism capabilities 5,6. Inter-individual differences in the speciation and amounts 
of arsenic metabolites have been reported among subjects chronically exposed to arsenic 7 and 
significant genetic determinants of arsenic metabolism was supported by epidemiological 
study 8. Toenail and hair arsenic has been reported to provided an integrated measure of 
internal arsenic exposure 9. However epidemiologic studies showed that external 
contamination lead to overestimation of internal dose and urinary arsenic concentration seems 
to be a better marker than concentrations in drinking water10. Growing epidemiological 
evidence also suggests that some factors such as age, sex and genetic susceptibility are related 
to its metabolism and can be important predictors for arsenic-related health hazard 11,12. 
1.1 Nature history of cardiovascular disease (CVD) 
Heart disease or cardiovascular disease is defined as the class of disease that involved the 
cardiac or blood vessels including arteries and veins. Although the term technically refers to 
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any disease that affects the cardiovascular system, it is usually to refer to those related to 
atherosclerosis and arterial disease since they shared similar conditions of causes, 
mechanisms and treatments13. The primary underlying disease process that leads to 
atherosclerosis is the deposition of lipid on the arterial surface progress to form plaques that 
reduced blood flow and induced blood clots that blocked flow entirely 14. 
Most countries face high and increasing rates of cardiovascular disease. In United States, 
mortality from heart and hypertensive diseases was greater than mortality from neoplasm. 
In recent years, cardiovascular risk in women has been increasing and has killed more 
women than breast cancer 15. The estimated age-adjusted mortalities of cardiovascular 
disease in US is 152.1 per 100,000 in year 2002 and is 48.3 in Taiwan 2005 16. By the time that 
heart problems are detected, the underlying causes, atherosclerosis, is usually quite 
advanced, have progressed for decades 17. Therefore increased emphasis on preventing 
atherosclerosis by modifying risk factors is remained important. 
1.2 Arsenic-related CVD 
Chronic arsenic exposure can lead to hyperkeratosis and loss of skin pigmentation as well as 
cancers of the skin, bladder, and lung. The international Agency for Research on Cancer 18 and 
the U.S. EPA 19 have classified arsenic as a group 1 and group A carcinogen based on human 
evidence. However, the mechanism of action for iAs-induced carcinogenicity is not known 20. 
Cardiovascular death is the major cause of mortality worldwide, and a small increased risk 
may imply a large quantity of excess mortality 21. Arsenic has also been shown to be a major 
risk factor of an unique form of peripheral vascular disease, Blackfoot disease (BFD) 22,23, 
especially in southwest Taiwan. Although the etiology of BFD development is still unclear, the 
dose-response relationships between arsenic and the prevalence of cardiovascular diseases 
have been documented including atherosclerosis, peripheral vascular disease (PVD), ischemic 
heart disease (IHD), hypertension, and cerebrovascular disease 21. IHD is a disease 
characterized by reduced blood supply to heart muscle, usually due to atherosclerosis of the 
coronary arteries. Its risk increases with age, smoking, hypercholesterolemia, diabetes, 
hypertension, and is more common in men and those who have close relatives with ischemic 
heart disease. Standard diagnosis of IHD including electrocardiogram, blood tests with cardiac 
enzymes, history and physical examinations. 
Although both population-based and occupational studies had shown that long-term 
exposure to inorganic arsenic has significant toxic effects on the cardiovascular system and 
the maximum arsenic contamination level in drinking water has been lowered from 0.05 to 
0.01 ppm by US Environmental Protection Agency in 2006. The allowable limit for arsenic in 
drinking water is 0.025 for Canada 24 and 0.05 ppm for Bengal, India, and Bangladesh 25. , 
the long-term association with chronic exposure to arsenic remains unclear and there is still 
epidemiological evidence needed for developing regulatory guidelines 26,27. 
1.3 Genetic factors associated with arsenic metabolism and CVD 
Although the mechanism of action for iAs-induced CVD hazards is not known 20. Proposed 
mechanisms include arsenic metabolism, pathogenesis of atherosclerosis and oxidative 
stress 28-30. More than one of these mechanisms may occur, and some may work together.  
1.4 Arsenic metabolism genes 
In general, the distribution of arsenic in human urine is 10-30% iAs, 10-20% MMA(V), and 
60-70% DMA(V) 6. However, some populations showed significant variation of arsenic 
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methylation levels in urine 31 which suggests that there are genetic factors in the regulation 
of the enzymes that metabolize arsenic, which may lead to difference in toxicity related to 
arsenic exposure. Not until recently have genes encoding enzymes that are responsible for 
arsenic metabolism been cloned and characterized. These genes include AS3MT and GSTO. 
The AS3MT gene directly encodes a cytosolic enzyme, arsenic methyltransferase, which 
catalyzes the multi-step process to convert inorganic arsenic to monomethyl arsenical 
(MMA) and dimethyl arsenical (DMA) 32. Glutathione S-transferases (GSTs) are Phase II 
detoxification enzymes that catalyze the conjugation of reduced glutathione (GSH) to a wide 
variety of endogenous and exogenous electrophilic compounds 33. A subfamily of GSTs, 
GST omega class,was shown to be identical with human monomethylarsonic acid (MMAV) 
reductase that is the rate-limiting enzyme for biotransformation of inorganic arsenic. 
Polymorphisms of GSTO genes were shown associated with the intracellular thiol status 
and arsenic biotransformation efficiency of the cell 34.  
1.5 Atherosclerosis- and CVD-related genes 
High-density lipoprotein (HDL) is postulated to prevent the development of atherosclerosis 
by inhibiting the oxidation of low-density lipoprotein (LDL). Human paraoxonase (PON1) is 
a serum esterase/lactonase transported on HDL particles which is considered the major 
determinant of the antioxidant action of HDL 35. Both in vitro studies and animal studies 
using PON1-knockout mice have shown that PON1 can prevent both HDL and LDL 
oxidation and therefore a protective enzyme against the development of atherosclerosis 36-38. 
Our previous data also showed significant synergistic effects of genetic variations in the 
PON gene cluster and chronic arsenic exposure on electrocardiogram abnormality 39. 
1.6 Other genes may linked to arsenic-related CVD 
A recent review article also pointed out that some other genes that associated with arsenic 
toxicity and altered gene expression in humans including genes involved in stress response, 
DNA damage response and apoptosis related genes, cell cycle regulatory genes and cell 
signaling and altered growth factor 40. Evidence from experimental studies had also 
suggested that arsenic increases the production of reactive oxygen species (ROS) 41-43. The 
induction of oxidative stress by arsenic may influence gene expression, inflammatory 
responses, and endothelial nitric oxide homeostasis 44, which play an important role in 
maintaining vascular tone. Genes involved in endogenous defenses against ROS thus may 
modify arsenic’s effect. Genetic material is constantly being subjected to insult from a wide 
range of DNA damage agents and this damage is controlled by the action of DNA repair 
enzymes.  
1.7 Arsenic-related early effect-biomarkers for CVD 
Preclinical or subclinical disease was defined as the pathological changes in the heart and 
arteries that develop early in the course of cardiovascular disease before symptoms or 
morbid events occur. They were developed before the evaluation of any of the risk factors or 
the determination of the subsequent incidence and mortality and thus are unbiased. Persons 
with subclinical disease, regardless of whether other risk factors are present, are at greater 
risk of future cardiovascular events than are those without subclinical disease 45. Although 
standard methods of cardiac risk assessment from the physical examination, laboratory 
tests, and treadmill exercise testing are often used clinically in cardiovascular disease 
stratification 46, evaluation of subclinical disease often not taken into account.  
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Epidemiology studies have showed that the population attributable fractions to CHD of 
subclinical disease was 36.8% and 42.5% for men and women respectively, which is much 
higher than for most of the known risk factors or combination of risk factors and further 
documents the importance of subclinical disease as a contributor to subsequent incident 
clinical disease 45. Among coronary artery disease (CAD) patients, the preoperative 
electrocardiogram (ECG) is shown to be predictive of long-term outcome independent of 
clinical findings and perioperative ischemia 47. Moreover, unrecognized silent myocardial 
infarction as diagnosed by electrographic changes is a major risk factor for subsequent 
myocardial infarction and coronary disease deaths 48, and it is also a useful additional tool 
for differentiating the x-lined form of hereditary cardiac myopathies 49. Subclinical disease 
and clinical disease shared similar risk factors and thus aggressive interventions to prevent 
clinical disease should be oriented to individuals with subclinical disease 50. 
Various ECG abnormalities have been observed among cases of acute arsenic poisoning and 
in acute promyelocytic leukemia patients treated with arsenic trioxide. Individuals exposed 
to excess arsenic through drinking water showed some of the ECG abnormalities 51. QT 
prolongation and dispersion have been implicated in the genesis of ventricular arrhythmia 
and directly predictors of cardiovascular and all-cause mortality 52,53. The gradient 
relationship of chronic arsenic poisoning and prolonged QT interval and increased QT 
dispersion has been reported recently 54,55 and arsenic-induced QT dispersion was 
associated with atherosclerosis disease and predicted cardiovascular mortality. However, 
evidence was based on risk assessment on subjects with previous exposure to high arsenic 
level and biomarkers for methylation metabolism were not considered. Besides, the 
accuracy and reproducibility of ECG reading including QT dispersion measurement have 
been restricted by difficulties with reliable determination of T-waves offset. Further study 
with a standardize measurement of ECG reading is warranted for a reliable assessment of 
ECG abnormality. 
Although an association between chronic arsenic exposure and CVD has been found in 
many studies, nearly all of these studies were limited by use of cross-sectional data, and 
longitudinal evidence by follow-up study was still limited. Besides, majority of previous 
studies were focus on the clinical arsenic-related cardiovascular disease, instead of the 
manifest of preclinical or subclinical detections. Morbidity and mortality from peripheral 
vascular disease, ischemic heart disease, and cerebral infarction are relative late clinical 
manifestations of chronic arsenic damage. These health effects may be the consequence of 
the interactions between predisposing and precipitating factors for cardiovascular diseases. 
The risk assessment based on these late cardiovascular events may be underestimated due 
to competing causes of death and the correctness in the diagnosis of the sudden death from 
cardiovascular diseases. Studies based on subclinical finding including ECG abnormality are 
needed to detect the early sign of chronic poisoning. 
Furthermore, the variation in distribution of arsenic in human urine across areas 31 
suggested that there are genetic factors in the regulation of the enzymes that metabolize 
arsenic, which may lead to difference in toxicity related to arsenic exposure. Association 
studies based on genetic polymorphisms have not provided consensus data that could 
generate a viable hypothesis on the molecular mechanism that determines the genetic basis 
of arsenic toxicity. The major objective of this study is to investigate the joint contribution of 
genetic factors including PON1, AS3MT, and GSTO gene families and the long-term arsenic 
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impacts on cardiovascular disease through measuring ECG abnormality as subclinical 
phenotypes and to evaluate whether the arsenic methylation patterns modifies the 
association between cumulative arsenic exposure and the risk of CVD.  
2. Materials and methods 
2.1 Study area and population  
The study included a community-based cohort from previous arseniasis-endemic area in 
southwestern Taiwan and a non-exposed population recruited from documented non-
endemic area in the same county with similar age, gender contribution and ecological status 
in 2002. The arseniasis-endemic area included Homei, Fusin and Hsinming villages in Putai 
Township on the southwestern coast of Taiwan which had been described previously 56-58. 
In short, residents in the study area consumed high-arsenic contaminated well water for 
decades since the 1910s because of the high salinity in shallow village wells 23. The arsenic 
concentration of artesian well water measured in the early 1960s was from 0.035 to 1.14 
ppm, with a median of 0.78 ppm 59,60. An estimated total daily amount of arsenic ingested by 
local residents was as high as 1 mg, mainly from drinking water 61. A tap water supply 
system was implemented in the area in the early 1960s and the entire arseniasis-endemic 
area has been supplied with municipal water since the early 1970s. The arsenic 
concentration of tap water supplied in the study area was less than 0.01 ppm 62. The original 
cohort established in 1989 including 1571 residents and 1081 subjects provided informed 
consents and enrolled in the study cohort. In 1993, 732 residents from the villages had a 12-
lead baseline Electrocardiogram (ECG) recorded. In 2002, after an average follow up period 
of eight years, 216 out of 380 subjects recruited provided a second ECG recording; 141 of 
them provided blood and urine specimens without an ECG recording; 229 were dead and 
their mortality determined through linkage with the national database; and the remaining 
146 were lost to follow-up. Among the 121 residents with normal baseline ECGs, 42 
developed an ECG abnormality at follow up. The non-exposed area was Chiali Township 
where the arsenic concentration of well water was very low according to the results of 
surveys conducted in 1960s and 1970s60,63. Climate, ethnic background (Han Chinese), 
urbanization degree and socioeconomic status were similar between Putai and Chiali. 
Frequency matching by age strata and gender were conducted for recruitment of resident 
and a total of 303 subjects were recruited.  
2.2 Measurement of arsenic exposure 
Arsenic level of well water for this study area was measured by the National Taiwan 
University group60. The water-contained arsenic recovery efficiencies were 95 percent or 
greater and were obtained using a PerkinElmer UV-VIS Spectrophotometer incorporating 
with Klett-Summerson Colorimeter. Detail validations of the water arsenic levels have been 
presented previously57,64. For villages which used more than one artesian well as a source of 
potable water, the medial levels of water arsenic contamination across those wells were 
assigned. The arsenic levels in artesian well water in this study area have been reported to 
be stable65. An index of cumulative arsenic exposure (micrograms per liter-years) were 
defined as the summation of products derived by multiplying the arsenic concentration (in 
micrograms per liter) in well water by duration of water consumption (in years) during 
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consecutive periods of living in the defacement villages. Both cumulative arsenic exposure 
and average arsenic concentrations in drinking water were calculated only for subjects who 
had complete information on arsenic exposure from drinking water throughout his or her 
lifetime. 
2.3 Questionnaire interview 
At both baseline and follow-up, well trained public health nurses carried out the 
standardized personal interview based on a structured questionnaire to acquire information 
regarding demographic and socioeconomic characteristics, artesian well water usage, 
residential history, lifestyle variables, personal and family disease history of hypertension, 
diabetes, and cardiovascular diseases. Cumulative arsenic exposure (in ppm-years) was 
derived from the median arsenic concentration in artesian well water (ppm) in the village 
where the subject lived and the duration of consuming the artesian well water (years)while 
residing in the village. The human Ethical Committee of the National Health Research 
Institutes in Taiwan approved the study protocol which based on the ethical standards 
formulated from the Helsinki Declarations of 1964 and revised in 2000 66. Informed consent 
was provided to each subject before participation. 
2.4 Biochemical measurements 
Fasting plasma was used for quantitative determination of blood glucose, cholesterol, 
triglycerides, high- and low-density lipoproteins, and urine acid were analyzed using the 
same instrument.  
Urinary samples were collected from each subject for arsenic species analyses. Subjects were 
asked not to consume seafood three days before urine collection. Arsenic species in urine 
including arsenite (AsIII), arsenate (AsV), monomethyl arsenical (MMA) and dimethyl 
arsenical (DMA) were quantified using high-performance liquid chromatography (HPLC) 
coupled with flow injection atomic absorption spectrometry. The HPLC system consisted of 
a solvent delivery pump (PU-1580, Jasco, Tokyo, Japan) and a silica-based anion-exchange 
column (Nucleosil 10 SB, 250 mm×4.6 mm; Phenomenex, CA, USA) with a guard column 
packed with the same material. A flow injection analysis system (FIAS-400, PerkinElmer, 
CT, USA) was designed as the on-line interface to the continuous hydride generation system 
(Analyst 100, PerkinElmer, CT, USA) used in this study. With this method, the within-say 
and between-day precision (coefficient of variance, CV%) for AsIII, AsV, MMA, and DMA 
determinations ranged from 1.0 to 3.7% were observed. Furthermore, the recoveries for 
AsIII, AsV, MMA, and DMA were 99.0, 98.9, 99.0, and 99.0% while the detection limits were 
0.75, 1.47, 1.19, and 0.76 μg/L, respectively. The primary methylation index (PMI) was 
defined as the ratio between MMA and iAs levels, and the secondary methylation index 
(SMI) was defined as the ratio between DMA and MMA.  
2.5 Genotyping 
Eight functional polymorphisms: C-108T (promoter), L55M (exon 3) and Q192R (exon 6) of 
PON1, A148G (exon 5) and C311S (exon 9) of PON2, M287T (exon 9) of AS3MT, A140D (exon 
4) of GSTO1, and N142D (exon 5) of GSTO2. SNPs were selected from NCBI’s SNP database 
based on prior implication in disease and minor allele frequency. Genomic DNA was extracted 
from whole blood using standard techniques. The AS3MT M287T polymorphism was 
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determined using a commercially designed TaqMan SNP Genotyping Assay (Applied 
Biosystems, USA). All other genotypes will be conducted by PCR amplification followed by 
polymorphism-specific restriction enzyme digestion and gel analysis. 
2.6 Physical examination 
Resting twelve-lead conventional ECG recording was performed at the Beimen Branch, 
Shinyin Hospital. Minnesota standardized code classification 1 was evaluated for both baseline 
and follow-up ECG readings at Epidemiological Cardiology Research Center (EPICARE), 
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-
Salem, North Carolina, USA (blinded to all other study data). ECG readings were classified 
into normal and abnormal (including minor and major abnormality) according to the 
definition of cardiac function by myocardial infarction or ischemia (Q wave and STT change) 
(MC_1, MC_4, MC_5, MC_92), conduction defect (MC_7), arrhythmias (MC_6, 
MC_81~MC_88), atrial enlargement or ventricular hypertrophy (LVH_MC3/LVH_CV), and 
prolonged ventricular repolarization. Fasting plasma was analyzed for blood glucose, 
cholesterol, triglycerides, high- and low-density lipoproteins, and urine acid by Beckmen 
SYNCHRON LX20 System (Beckman Coulter, Fullerton, CA). 
2.7 Statistical analysis  
Differences in demographic characteristics and cardiovascular risk factors between ECG 
normal and abnormal subjects were assessed. Continuous variables were expressed as mean  
standard deviation (SD) and evaluated by student’s t or Wilcoxon rank-sum test. Categorical 
variables were expressed as proportions and compared using chi-square test or Fisher’s exact 
test. Allele frequencies, genotype frequencies, and Hardy-Weinberg equilibrium were assessed 
separately in ECG abnormal and normal groups using SAS-genetics package. Relative 
distribution of polymorphisms in the ECG abnormal and ECG normal groups was assessed by 
chi-square analyses. Linkage disequilibrium (LD) as measured by D’ was assessed using 
Haploview 4.0 (http://www.broad.mit.edu/mpg/haploview/). Haplotypes and tag SNPs 
were inferred using SAS. Logistic regression analysis was used to assess the effect of 
cardiovascular risk factors and genetic polymorphisms in relation to ECG abnormality. 
Arsenic exposure and ECG abnormality in between study subjects in Putai and Chiali areas 
were also compared. Arsenic exposure in Putai area were stratified into two categories by 
median levels and subjects in Chiali area were used as reference group, and a trend test was 
conducted to evaluate the dose-relationship. ANOVA was conducted to evaluate urinary 
arsenic species between subjects with normal and abnormal ECG reading. A p value <0.05 was 
considered statistically significant. Permutation test, a significance test used to obtain the 
unknown reference distribution by calculating all possible values of the test statistic under 
random rearrangements of the disease status on the observed study subjects , was used to 
control for type 1 error for multiple testing due to the limited sample size, and the empirical p-
values were reported 67. Statistical analyses were conducted using SAS version 9.1 (SAS, Inc., 
Cary, NC). 
3. Results 
Baseline characteristics of arsenic exposure and cardiovascular risk factors among study 
subjects are summarized in Table 1. A total of 42 incident cases among the 121 baseline-
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normal study subjects showed ECG deterioration at follow-up. Compared to ECG normal 
subjects, those with an ECG abnormality had significantly higher arsenic exposure as shown 
by both years of drinking artesian water and cumulative arsenic exposure index. Age and 
proportion of cigarette smoking in the ECG abnormal group tended to be higher but did not 
reach statistical significance. No differences were observed in other cardiovascular risk 
factors including gender, alcohol consumption, BMI, serum lipids, blood pressure, and 
plasma glucose. 
 
Variable 
ECG normal 
(n=79) 
ECG abnormal 
(n=42) 
Age (years) 62.0 ± 7.3 64.9 ± 8.7 
Male (% ) 29 (36.7) 18 (42.9) 
Cigarette Smoking (%) 14 (17.7) 13 (31.0) 
Alcohol consumption (%) 10 (12.7) 6 (14.3) 
Residency (years) 41.5 ± 12.4 43.3 ± 14.3 
Drinking Artesian Water (years) 19.2 ± 9.3 25.1 ± 9.7 
Cumulative As exposure (ppm-years) 13.6 ± 8.4 18.0 ± 8.4 
BMI (kg/m^2) 24.9 ± 3.13 24.5 ± 3.4 
Triglycerides (mg/dl) 113.1 ± 64.7 132.3 ± 106.9 
Total Cholesterol (mg/dl) 220.2 ± 45.0 211.7 ± 42.5 
HDL (mg/dl) 60.3 ± 18.1 59.2 ± 14.3 
LDL (mg/dl) 121.9 ± 48.1 124.6 ± 76.3 
Cholesterol /HDL ratio 4.0 ± 1.6 3.8 ± 1.2 
Uric acid (mg/dl) 6.1 ± 1.9 5.7 ± 1.8 
SBP (mmHg) 124.8 ± 19.3 128.2 ± 17.3 
DBP (mmHg) 82.2 ± 11.1 84.2 ± 8.6 
AC glucose (mg/dl) 98.6 ± 23.1 104.4 ± 37.3 
PC glucose (mg/dl) 127.3 ± 52.2 129.1 ± 78.1 
Data are reported as mean ± SD or counts (%) 
HDL: high density lipoprotein; LDL: low density lipoprotein; CHOL: total cholesterol levels; SBP: 
systolic blood pressure; DBP: diastolic blood pressure, AC: ante cibum, PC: post cibum 
Table 1. Baseline characteristics of arsenic and CVD risk factors among baseline-normal 
study participants classified by ECG status at follow-up 
3.1 Univariate SNPs association analysis 
Eight functional polymorphisms: C-108T, L55M and Q192R of PON1, A148G and C311S of 
PON2, M287T of AS3MT, A140D of GSTO1, and N142D of GSTO2 were screened for 
association with ECG abnormality and Hardy-Weinberg equilibrium (HWE). None reached 
statistical significance, suggesting no univariate SNP association in the analysis. Genotypic 
frequencies of M287T showed a significant departure from HWE but because of the limited 
number of participants carrying the T alleles in this study population, they were excluded 
from subsequent analysis.  
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Gene 
SNP 
ECG status  
Normal Abnormal OR (95% CI) 
PON1 Q192R    
 RR 18 14 1.00 (reference) 
 QR 27 9 0.43 (0.15-1.20) 
 QQ 11 3 0.35 (0.08-1.50) 
 L55M    
 LL 48 21 1.00 (reference) 
 LM 14 4 0.65 (0.19-2.22) 
 MM 0 0 - 
 C-108T    
 CC 17 7 1.00 (reference) 
 CT 30 15 1.21 (0.41-3.56) 
 TT 15 6 0.97 (0.27-3.54) 
PON2 C311S    
 SS 31 18 1.00 (reference) 
 CS 24 7 0.50 (0.18-1.40) 
 CC 2 2 1.72 (0.22-13.30) 
 A148G    
 AA 30 15 1.00 (reference) 
 AG 28 10 0.71 (0.28-1.85) 
 GG 3 2 1.33 (0.20-8.86) 
AS3MT M287T    
 MM 67 30 1.00 (reference) 
 MT 2 1 1.12 (0.10-12.80) 
 TT 0 0 - 
GSTO1 A140D    
 AA 41 21 1.00 (reference) 
 AD 22 9 0.80 (0.31-2.04) 
 DD 5 2 0.78 (0.14-4.37) 
GSTO2 N142D    
 NN 35 16 1.00 (reference) 
 ND 30 14 1.02 (0.43-2.43) 
 DD 4 2 1.09 (0.18-6.60) 
Hardy-Weinberg Equilibrium (HWE) test was conducted among all study subjects 
Table 2. Association of SNPs and Hardy-Weinberg equilibrium test 
Figure 1 shows the related position and linkage disequilibrium (LD) between SNPs in the 
PON and GSTO gene clusters. Two SNPs within PON2 (C311S and A148G) and GSTO1-
A140D and GSTO2-N142 were in high LD but SNPs within PON1 or adjacent SNPs 
between PON1 and PON2 (C-108T and C311s) had low LD measurements, implying they 
were not in the same LD block. Q192R, C-108T, C311S and A140D were identified as tag-
SNPs. 
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Fig. 1. Linkage disequilibrium (LD) plot of PON1 and GSTO gene clusters in 121 study 
subjects. The measure of LD (D’) among all possible pairs of SNPs is shown graphically. 
Dark red represents high D’ while white represents low D’ 
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3.2 Haplotype analysis and association with ECG abnormality 
Haplotypes of PON1, PON2, GSTO1, GSTO2 and tag-SNPs of the PON gene cluster were 
constructed, and those whose frequencies were <5% were excluded from association 
analysis (Table 3). Overall, the effects of these haplotypes on ECG abnormality were not 
statistically significant after 10,000 permutations; however, the haplotype R-C-S constructed 
by Q192R, C-108T and C311S had the highest odds, 1.92 (95% CI: 0.76-4.85) times increased 
risk toward ECG abnormality. 
 
Haplotypes ECG normal ECG abnormal OR 
Q192R L55M C-108T    
R L T 46 (37.1%) 24 (42.9%) 1.00 (reference) 
Q L C 38 (30.7%) 10 (17.9%) 0.50 (0.22-1.18) 
R L C 18 (14.5%) 15 (26.8%) 1.60 (0.69-372) 
Q M C 8 (6.5%) 4 (7.1%) 0.96 (0.26-3.51) 
Q L T 8 (6.5%) 3 (5.4%) 0.72 (0.17-2.96) 
      
Q192R C-108T     
R T  52 (41.9%) 24 (42.9%) 1.00 (reference) 
Q C  46 (37.1%) 14 (25.0%) 0.66 (0.31-1.42) 
R C  18 (14.5%) 15 (26.8%) 1.81 (0.78-4.18) 
Q T  8 (6.5%) 3 (5.4%) 0.81 (0.20-3.33) 
      
C311S A148G     
S A  89 (71.8%) 40 (70.4%) 1.00 (reference) 
C G  32 (25.8%) 10 (17.9%) 0.70 (0.31-1.56) 
      
A140D N142D     
A N  96 (69.5%) 43 (67.2%) 1.00 (reference) 
D D  28 (20.3%) 10 (15.6%) 0.80 (0.36-1.77) 
A D  10 (7.3%) 8 (12.5%) 1.79 (0.66-4.84) 
      
Q192R C-108T C311S    
R T S 47 (37.9%) 21 (37.5%) 1.00 (reference) 
Q C S 27 (21.7%) 9 (16.1%) 0.75 (0.30-1.86) 
R C S 14 (11.3%) 12 (21.4) 1.92 (0.76-4.85) 
Q C C 19 (15.3%) 5 (8.9%) 0.59 (0.19-1.79) 
Q T S 8 (6.5%) 3 (5.4%) 0.84 (0.20-3.48) 
Haplotypes with a frequency less than 5% were removed. 
Empirical P-value: a Haplotype-specific test, b Haplotype-global test 
Table 3. Estimated haplotype frequencies and haplotypes association analysis with ECG 
abnormality 
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The relative odds of lipid profiles for PON-haplotype R-C-S carrier compared with non-
carriers are shown in Figure 2. The R-C-S haplotype was positively correlated with higher 
serum HDL-cholesterol, LDL-cholesterol, and triglyceride levels without statistical 
significance, but was significantly associated with increased total cholesterol levels 
(OR=2.91, 95% CI: 1.13-7.70). 
 
 
 
 
Fig. 2. Odds ratios of lipid profiles for Q192R, C-108T and C311S R-C-S haplotype carrier 
among study subjects (N=121) 
3.3 Synergistic association of PON haplotype and arsenic on ECG abnormality 
The synergistic associations between PON haplotype and arsenic exposure are summarized 
in Table 4. The PON R-C-S haplotype carrier with higher cumulative arsenic exposure 
(greater than the median value of 14.7 ppm-years) showed a >14.66 (95% CI: 1.83-117.64) 
increased risk for ECG abnormality compared to non-RCS haplotype carriers with low 
cumulative arsenic exposure (<14.7 ppm-years) (Table 4a). The PON R-C-S haplotype carrier 
with more years of drinking artesian water (greater than the median of 21 years) had a 
10.83-fold (95% CI: 1.83-64.03) increased risk (Table 4b). These associations were even 
stronger after adjusting for age, gender, and cigarette smoking, when the odds increased to 
19.19 (95% CI: 1.86-197.76) and 21.09 (95% CI: 2.77-160.35) for cumulative exposure index 
and drinking years, respectively. 
Table 5 showed the correlation between cumulative arsenic exposure and urinary arsenic 
species from arsenic endemic and non-endemic areas in southwestern Taiwan. Subjects 
with higher cumulative arsenic exposure had significantly higher levels of As (III), iAs, 
MMA, Summation of iAs and MMA. However, DMA levels and SMI were significantly 
lower among subjects with high arsenic exposure. Similar pattern was observed when 
urinary arsenic was analyzed in percentage. Subjects with higher cumulative arsenic 
exposure had higher percentages of As(III), iAs and MMA in urinary and lower DMA 
percentage.  
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R-C-S CAE 
ECG 
Normal
ECG 
Abnormal 
OR (95% CI) OR (95% CI)a 
Empirical 
P-value a 
- - 22 3 1.00 (reference) 1.00 (reference) - 
+ - 8 2 1.83 (0.26-13.06) 1.57 (0.19-13.00) 0.319 
- + 17 11 4.74 (1.14-19.72) 4.27 (0.83-22.08) 0.632 
+ + 2 4 14.66 (1.83-117.64) 19.19 (1.86-197.76) 0.014 
a Permutation analysis adjusted by age, gender and cigarette smoking 
CAE: Cumulative arsenic exposure (ppm-years) 
R-C-S: Q192R, C-108T and C311S R-C-S haplotype 
Table 4a. Synergistic effects of Q192R, C-108T, and C311S R-C-S haplotypes carrier and high 
cumulative arsenic exposure (CAE) (> median of 14.7 ppm-years) on ECG abnormality 
 
R-C-S DAW 
ECG 
Normal
ECG 
Abnormal 
OR (95% CI) OR (95% CI)a 
Empirical 
P-value a 
- - 26 3 1.00 (reference) 1.00 (reference) - 
+ - 8 2 2.17 (0.31-15.33) 1.90 (0.24-14.94) 0.190 
- + 19 15 6.84 (1.73-27.02) 10.66 (2.12-53.55) 0.055 
+ + 4 5 10.83 (1.83-64.03) 21.09 (2.77-160.35) 0.010 
a Permutation analysis adjusted by age, gender and cigarette smoking 
DAW: Drinking artesian water (years) 
RCS: Q192R, C-108T & C311S R-C-S haplotype 
Table 4b. Synergistic effects of Q192R, C-108T, and C311S R-C-S haplotypes carrier and 
more years of drinking artesian water (DAW) (> mean of 21 years) on ECG abnormality 
 
Variable  Non-exposed 
(Chiali) (N=302) 
≤ 14.7 (Putai) 
(N=191) 
> 14.7 (Putai) 
(N=103) 
Urinary arsenic level    
As (III) (μg/g creatinine)** 2.07 (2.98) 4.61 (9.46) 4.73 (6.24) 
As (V) (μg/g creatinine) 2.78 (3.16) 3.13 (3.66) 2.21 (1.92) 
iAs (μg/g creatinine)** 4.85 (4.66) 7.73 (11.54) 6.95 (6.74) 
MMA (μg/g creatinine)** 3.13 (3.79) 4.48 (6.30) 4.21 (3.25) 
Σ(iAs +MMA) (μg/g creatinine)** 7.98 (6.84) 12.21 (14.66) 11.15 (7.84) 
DMA (μg/g creatinine)* 42.87 (34.48) 33.64 (27.34) 37.37 (24.32) 
Σ(iAs + MMA + DMA) 
(μg/g creatinine) 50.85 (37.86) 45.87 (33.60) 48.58 (28.53) 
PMI (MMA/iAs) 0.87 (1.02) 0.84 (0.75) 0.85 (0.60) 
SMI (DMA/MMA)** 23.68 (22.80) 15.44 (28.38) 15.94 (20.86) 
Urinary arsenic percentage     
As (III) %** 4.59 (5.18) 10.08 (13.22) 9.18 (9.08) 
As (V) %** 6.23 (5.62) 8.27 (7.76) 5.81 (7.58) 
iAs %** 10.82 (8.37) 18.35 (16.50) 14.99 (10.73) 
MMA %** 7.45 (8.59) 10.90 (9.05) 10.12 (7.57) 
DMA %** 81.73 (13.84) 70.75 (20.23) 74.89 (13.99) 
a P-value for ANOVA 
*P-value < 0.05, ** P-value < 0.01 
Table 5. Correlation of cumulative arsenic exposure and urinary metabolism capacity 
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Distribution between levels of cumulative arsenic exposure and ECG abnormality was 
summarized in Table 6. Significant dose-response relationships were observed between 
higher levels of cumulative arsenic exposure and ECG reading regarding abnormalities, 
myocardial infarction or ischemia disease, and also atrial enlargement and ventricular 
hypertrophy. Increased cumulative arsenic exposure was also correlated with a higher 
proportion of abnormality in prolonged ventricular repolarization however not reach 
statistical significance. 
 
Variable  Non-exposed 
(Chiali) (N=302)
≤ 14.7 (Putai) 
(N=191) 
> 14.7 (Putai) 
(N=103) 
ECG reading (ECG group)**    
  0: Normal 155 (51.3) 96 (50.3) 40 (38.8) 
  1: Minor abnormal 122 (40.3) 70 (36.7) 40 (38.8) 
  2: Major abnormal 25 (8.3) 25 (13.0) 23 (22.4) 
Myocardial Infarction or Ischemia (MC_MI)*    
  0: Normal 216 (71.5) 136 (71.2) 68 (66.0) 
  1: Minor abnormal 72 (23.8) 37 (19.4) 20 (19.4) 
  2: Major abnormal 14 (4.6) 18 (9.4) 15 (14.6) 
Conduction defect (BBB; Bundle Branch Block)   
  0: Normal 261 (86.4) 174 (91.1) 86 (83.5) 
  1: Abnormal 41 (13.6) 17 (8.9) 17 (16.5) 
Arrhythmia (Arrhythmia)    
  0: Normal 265 (87.8) 170 (89.0) 97 (94.2) 
  1: Abnormal 37 (12.3) 21 (11.0) 6 (5.8) 
Atrial enlargement/Ventricular hypertrophy (Hypertrophy)** 
  0: Normal 286 (94.7) 167 (87.4) 85 (82.5) 
  1: Abnormal 16 (5.3) 24 (12.6) 18 (17.5) 
Prolonged ventricular repolarization (Long_QT)   
  0: Normal 299 (99.0) 187 (98.0) 99 (96.1) 
  1: Abnormal 3 (1.0) 4 (2.0) 4 (3.9) 
a P-value for trend test 
*P-value < 0.05, ** P-value < 0.01 
Table 6. Distribution of ECG reading by cumulative arsenic exposure 
4. Discussion 
Various ECG abnormalities have been observed among cases of acute arsenic poisoning and 
in acute promyelocytic leukemia patients treated with arsenic trioxide. Individuals exposed 
to excess arsenic through drinking water showed some of the ECG abnormalities51. Several 
epidemiologic studies showed that QT prolongation and increased CVD mortality among 
high levels of arsenic-exposed subjects. However, the results might not be applicable in 
subjects with low to moderate arsenic. Our data replicated this association in an arseniasis-
endemic area and a well-matched control area which no previous history of water 
contamination. We highlighted the correlation between previous chronic arsenic exposure 
and ECG abnormalities after cessation of arsenic-contaminated water consumption for 
decades.  
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The major strength of this study was to apply a standardized Minnesota coding 
classification of ECG reading that ensures good quality assurance and control. Furthermore, 
detailed parameters regarding ECG abnormalities allowed us to evaluate the minor changes 
due to arsenic toxicity. In current analyses, higher duration of arsenic water consumption 
was associated with ECG abnormality, myocardial infarction or ischemia, atrial enlargement 
or ventricular hypertrophy in a dose-response relationship. Besides, it was also positively 
correlated to arrhythmia and prolonged ventricular repolarization without reached the 
statistical significance. Moreover, higher levels of cumulative arsenic exposure were also 
associated with ECG parameters including higher PR duration, QRS duration and QRS axis 
and smaller JT duration, JT index and RaVL (data not shown).  
There were still some limitations for this study. First, results from this study were based on 
a population with history of arsenic exposure. Insignificant association between urinary 
methylation capabilities might due to attrition of high-level arsenic exposed subjects, 
competing risks for CVD mortality was not considered in current analysis. Another 
limitation of the present study was that the measurement of urinary metabolism species and 
physical evaluation were conducted at a cross-sectional design. The causal-relationship 
between urinary species of arsenic and ECG abnormality could not be inferred given current 
evidence. However, the previous exposure status was significantly correlated with current 
urinary arsenic species implied it was more efficient among subjects after cessation of long-
term exposure to high levels of arsenic. These results may have implications for arsenic 
mediation strategies in areas currently exposed to potentially harmful levels of arsenic in 
drinking water. Furthermore, CVD usually took years for disease development. Correlation 
may be biased due to unmeasured factors during a relative short follow-up period. Longer 
duration of follow-up with serial changes for ECG abnormality would help better 
understand the underlying mechanism regarding arsenic-induced hazards. 
The major significance by this study was the assessment of arsenic risk from subjects 
without exposure of inorganic arsenic to moderate and relatively high levels of cumulative 
arsenic exposure. Causal inference can be strengthened by the dose-response relationship by 
the stronger effect in a susceptible subgroup of the population. Besides, this study 
demonstrated significant gene-gene and gene-environment interactions by showing PON1 
gene cluster including polymorphisms of PON1: Q192R, PON1: C-108T, and PON2: C311S 
and latent effect of arsenic exposure on incidence of ECG abnormality. Besides, PON2: 
C311S was independently associated with LDH elevation and further predicted future CVD 
mortality independent to other conventional risk factors including age, gender, cigarette 
smoking, hypertension and diabetes mellitus. After cessation of arsenic-contaminated water 
consumption for decades, biomarkers for CVD mortality and morbidity was still associated 
with reduced risks for arsenic and attributable to underlying genetic predisposition. Such 
data may also help risk assessment in the population and provide knowledge about the 
underlying mechanisms. 
HDL has been shown to prevent atherogenesis in vivo and in vitro through anti-oxidative 
and anti-inflammatory activities35. The major part of anti-atherogenic properties associated 
with HDL is explained by the activity of Paraoxonase 168. Both PON1 and PON2 belong to 
the protein family of Paraoxonase 1 that includes PON3 which has been suggested that 
involved in CVD69. PON1 directly form part of HDL particles whereas PON2 found in 
endothelial cells, smooth muscle cells and macrophages that possesses antioxidant 
properties similar to PON1 by delays cellular oxidative stress and prevents apoptosis in 
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vascular endothelial cells70,71. Regarding three common polymorphisms in coding region of 
the human PON1 gene, the frequencies of Q192R, L55M, and C-108T for Taiwanese 
population were similar to those reported in the literature for the Chinese population 72,73. 
Besides, we confirmed that paraoxonase, diazoxonase and arylesterase activities were 
directly influenced by the Q192R and C-108T polymorphisms. Previous studies had also 
shown that 311 C allele in PON2 was associated with increased risks of coronary artery 
disease, MI and also diabetic nephropathy74-76. Our data confirmed the significance of 
PON2: C311S polymorphism during pathogenesis of CVD among chronic arsenic exposed 
subject. This finding could help to identify subjects at higher risk of cardiovascular damage 
for arsenic toxicity. 
However, some other factors that might have influenced the arsenic methylation profiles 
were not considered. Nutritional status and dietary intake may also be uncontrollable 
factors. Besides, we could not obtain the accurate data on allele distribution three 
polymorphisms: PON1: C-108T, GSTO1:A140D, and AS3MT: L55M in our samples. We still 
could not rule out the intra- and inter-individual variability to arsenic methylation and also 
their impacts on pathogenesis of CVD morbidity and mortality. Besides, the arsenic levels in 
rice growing in the arsenic contaminated area or inorganic arsenic from fish intake may be 
elevated. This might potentially increase arsenic exposure in the endemic area77-80. Future 
study of exposure assessment is needed. In addition, arsenic exposure has also been shown 
to alter the methylation level of both global DNA and certain genes in studies that analyzed 
a limited number of epigenetic endpoints81. Therefore, it is necessary to enlarge sample size 
for the evaluation of genetic association and ECG abnormality and other confounders that 
may be directly related to arsenic risks. 
Genome-wide association studies (GWAS) have been applied in the search for suscepitibility 
genes to coronary artery disease, myocardial infarction and heart failure82-84. However, none 
of the candidate regions and genes showed a powerful association with CVD at genome-
wide significance and the molecular and biological mechanisms remains unclear. 
Atherosclerosis is a multifactorial disease that may lead to myocardial infarction or heart 
failure. A conservative estimate would be that at least 100 genes have the potential to affect 
the modifying factors including atherosclerosis, myocardial infarction and congestive heart 
failure with each having a genetic contribution of as much as 2% to the phenotype84. Since 
CVD usually took years to develop, correlation may be biased due to unmeasured factors 
during a relative short follow-up period or relatively underestimated by competing risk. 
Our studies with longer duration of follow-up with serial changes for ECG abnormality did 
help better understand the underlying mechanism and duration regarding arsenic-induced 
hazards. These findings emphasize the importance of long term arsenic effect, along with 
the necessity of intensive follow-up for preclinical or subclinical phenotypes such as ECG 
abnormality for preventing excessive CVD mortality. 
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